期刊文献+

小承气汤保留灌肠防治TIPS术后并发肝性脑病的护理观察 被引量:10

Nursing observation of Xiaochengqi decoction retention enema in prevention of complicated hepatic encephalopathy after TIPS
下载PDF
导出
摘要 目的探讨小承气汤保留灌肠防治经颈静脉肝内门体分流术(TIPS)术后并发肝性脑病的护理效果。方法分析60例TIPS术患者的临床资料,依据是否给予针对保留灌肠护理措施进行分组,随机分为对照组(30例)和观察组(30例),对照组对于TIPS术患者给予纠正电解质失衡、控制感染等支持性护理措施,针对性的给予静脉滴注支链氨基酸,观察组在对照组治疗护理基础上在TIPS术后即采用小承气汤保留灌肠。观察两组临床效果。结果两组患者术前血氨、谷丙转氨酶、白蛋白、总胆红素和术后白蛋白比较,差异均无统计学意义(P>0.05),术后观察组血氨、谷丙转氨酶、总胆红素和肝性脑病发生率均优于对照组,差异均有统计学意义(P<0.05)。结论小承气汤保留灌肠可以有效的预防TIPS术后肝性脑病的发生率,提高患者预后水平。 Objective To investigate the nursing effect of Xiaochengqi decoction retention enema in prevention of complicated hepatic encephalopathy after transjugular intrahepatic portosystem stent-shunt (TIPS). Methods Clinical data of 60 TIPS patients were analyzed. They were divided into control group (30 cases) and observation group (30 cases) by retention enema measures. The control group received support nursing measure of electrolyte imbalance correcting and infection control with targeted branched chain amino acid by intravenous drip. The observation group received additional Xiaochengqi decoction after TIPS. Clinical effects of the two groups were observed. Results There were no statistically significant differences of preoperative blood ammonia, glutamic-pyruvic transaminase, albumin, total bilirubin, and postoperative albumin between the two groups (P>0.05). After treatment, the observation group had better blood ammonia, glutamic-pyruvic transaminase, total bilirubin, and incidence of hepatic encephalopathy than the control group, and the difference had statistical significance (P<0.05). Conclusion Xiaochengqi decoction retention enema can effectively prevent the incidence of hepatic encephalopathy after TIPS, and improve prognosis level in patients.
出处 《中国实用医药》 2015年第9期214-216,共3页 China Practical Medicine
关键词 小承气汤 保留灌肠 经颈静脉肝内门体分流术 肝性脑病 Xiaochengqi decoction Retention enema Transjugular intrahepatic portosystem stent-shunt Hepatic encephalopathy
  • 相关文献

参考文献6

二级参考文献38

  • 1徐莉英.评估低钠血症和MELD评分对肝硬化病人预后的价值[J].世界感染杂志,2005,5(5):416-417. 被引量:4
  • 2Yang Z, Han G, Wu Q, et al. Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents:a meta- analysis. J Gastroenterol Hepatol, 2010, 25: 1718-1725.
  • 3wRiggio O, Angeloni S, Salvatori FM, et al. Incidence,natural history, and risk factors of hepatic encephalopathy after transjugular intra- hepatic portosystemic shunt with polytetrafluoroethylene-coveredstent grafts. Am J Gastroenterol, 2008, 103: 2738-2746.
  • 4Riggio O, Ridola L, Pasquale C, et al. Evidence of persistent cogni- tive impairment after resolution of overt hepatic encephalopathy. .Clin Gastroenterol Hepatol, 2010, 9: 181-183.
  • 5Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy-- definition,nomenclature, diagnosis,and quantification: final report of the working party at the llth World Congresses of Gastroenterology, Vienna,1998. Hepatology, 2002, 35: 716-721.
  • 6Nolte W, Wiltfang J, Schindler C, et al. Portosystemic hepatic en- cephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis:clinical,laboratory, psychometric,and electroencephalographic investigations. Hepatology, 1998, 28:1215- 1225.
  • 7H~iussinger D, Schliess F.Pathogenetic mechanisms of hepatic encephalopathy. Gut, 2008, 57:1156-1165.
  • 8Hassoun Z, Deschnes M, Lafortune M, et al. Relationship between pre-TIPS liver perfusion by the portal vein and the incidence of post- TIPS chronic hepatic encephalopathy. Am J Gastroenterol, 2001, 96: 1205-1209.
  • 9Mamiya Y, Kanazawa H, Kimura Y, et al. Hepatic encephalopathy after transjugnlar intrahepatic portosystemic shunt. Hepatol Res, 2004, 30: 162-168.
  • 10Stewart CA, Malinchoc M, Kim WR, et al. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl, 2007, 13: 1366-1371.

共引文献51

同被引文献247

引证文献10

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部